SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-26-001382 to NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)

NEONC TECHNOLOGIES HOLDINGS, INC.
Date: Feb. 10, 2026 · CIK: 0001979414 · Accession: 0000000000-26-001382

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-293281

Date
February 10, 2026
Author
Amir Farrokh Heshmatpour
Form
UPLOAD
Company
NEONC TECHNOLOGIES HOLDINGS, INC.

Letter

February 10, 2026 Amir Farrokh Heshmatpour Chief Executive Officer NeOnc Technologies Holdings, Inc. 23975 Park Sorrento, Suite 205 Calabasas, CA 91302 Re:NeOnc Technologies Holdings, Inc. Registration Statement on Form S-1 Filed February 6, 2026 File No. 333-293281 Dear Amir Farrokh Heshmatpour: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Thomas J. Poletti, Esq.

Show Raw Text
February 10, 2026
Amir Farrokh Heshmatpour
Chief Executive Officer
NeOnc Technologies Holdings, Inc.
23975 Park Sorrento, Suite 205
Calabasas, CA 91302
Re:NeOnc Technologies Holdings, Inc.
Registration Statement on Form S-1
Filed February 6, 2026
File No. 333-293281
Dear Amir Farrokh Heshmatpour:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Thomas J. Poletti, Esq.